KR20040068877A - 안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물 - Google Patents
안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물 Download PDFInfo
- Publication number
- KR20040068877A KR20040068877A KR1020040005089A KR20040005089A KR20040068877A KR 20040068877 A KR20040068877 A KR 20040068877A KR 1020040005089 A KR1020040005089 A KR 1020040005089A KR 20040005089 A KR20040005089 A KR 20040005089A KR 20040068877 A KR20040068877 A KR 20040068877A
- Authority
- KR
- South Korea
- Prior art keywords
- amlodipine camsylate
- solvent
- amorphous
- camsylate
- amorphous amlodipine
- Prior art date
Links
- UXKMFEPPKJZDAR-STOWLHSFSA-N [(1r,4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl UXKMFEPPKJZDAR-STOWLHSFSA-N 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000003960 organic solvent Substances 0.000 claims abstract description 13
- 238000001694 spray drying Methods 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims abstract description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000002148 esters Chemical class 0.000 claims abstract description 5
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 238000001556 precipitation Methods 0.000 claims abstract description 5
- 239000007789 gas Substances 0.000 claims abstract description 4
- 229910052786 argon Inorganic materials 0.000 claims abstract description 3
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 3
- 150000002576 ketones Chemical group 0.000 claims abstract description 3
- 150000002825 nitriles Chemical class 0.000 claims abstract description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000003570 air Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- 229960000528 amlodipine Drugs 0.000 description 8
- -1 2-aminoethoxy-methyl Chemical group 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 229960004005 amlodipine besylate Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- E—FIXED CONSTRUCTIONS
- E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
- E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
- E06B5/00—Doors, windows, or like closures for special purposes; Border constructions therefor
- E06B5/10—Doors, windows, or like closures for special purposes; Border constructions therefor for protection against air-raid or other war-like action; for other protective purposes
- E06B5/16—Fireproof doors or similar closures; Adaptations of fixed constructions therefor
- E06B5/161—Profile members therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2255/00—Coating on the layer surface
- B32B2255/08—Coating on the layer surface on wood layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/30—Properties of the layers or laminate having particular thermal properties
- B32B2307/306—Resistant to heat
- B32B2307/3065—Flame resistant or retardant, fire resistant or retardant
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05Y—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES E05D AND E05F, RELATING TO CONSTRUCTION ELEMENTS, ELECTRIC CONTROL, POWER SUPPLY, POWER SIGNAL OR TRANSMISSION, USER INTERFACES, MOUNTING OR COUPLING, DETAILS, ACCESSORIES, AUXILIARY OPERATIONS NOT OTHERWISE PROVIDED FOR, APPLICATION THEREOF
- E05Y2900/00—Application of doors, windows, wings or fittings thereof
- E05Y2900/10—Application of doors, windows, wings or fittings thereof for buildings or parts thereof
- E05Y2900/13—Type of wing
- E05Y2900/132—Doors
- E05Y2900/134—Fire doors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Civil Engineering (AREA)
- Structural Engineering (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
염 | 용해도 (㎎/㎖) | 포화시 pH |
결정형 암로디핀 베실레이트 | 2.35 | 6.2 |
결정형 암로디핀 캠실레이트 | 1.42 | 6.2 |
무정형 암로디핀 캠실레이트 | 6.59 | 6.2 |
시험 제제 | 초기 | 2개월 | 4개월 |
무정형 암로디핀 캠실레이트 정제 | 100.3±0.9% | 99.0±0.7% | 98.0±1.3% |
무정형 암로디핀 베실레이트 정제 | 102.7±1.3% | 92.7±1.8% | - |
Claims (7)
- 결정형 암로디핀 캠실레이트를 유기용매에 용해시키고, 생성된 용액으로부터 용매를 제거하여 무정형 암로디핀 캠실레이트를 회수하는 것을 포함하는, 무정형 암로디핀 캠실레이트의 제조 방법.
- 제1항에 있어서, 유기 용매가 케톤류, 알콜류, 니트릴류, 에테르류, 에스테르류, 염소화 용매 및 이들의 혼합물로 이루어진 그룹에서 선택되는 것을 특징으로 하는 방법.
- 제2항에 있어서, 유기 용매가 에탄올과 메틸렌 클로라이드의 혼합물인 것을 특징으로 하는 방법.
- 제1항에 있어서, 용매를 제거하는 수단이 분무 건조법, 로울러 건조법, 용매침전법, 동결건조법 및 급속 용매제거법으로 이루어진 그룹에서 선택된 방법인 것을 특징으로 하는 방법.
- 제4항에 있어서, 용매를 제거하는 수단이 건조 가스로서 질소, 아르곤, 이산화탄소 또는 공기를 사용하는 분무 건조법인 것을 특징으로 하는 방법.
- 제1항 내지 제5항 중 어느 한 항의 방법에 따라 제조된 무정형 암로디핀 캠실레이트.
- 제6항의 무정형 암로디핀 캠실레이트를 활성 성분으로서 포함하는 심장 혈관계 질환 치료용 약학적 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030005227 | 2003-01-27 | ||
KR1020030005227 | 2003-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040068877A true KR20040068877A (ko) | 2004-08-02 |
KR100558505B1 KR100558505B1 (ko) | 2006-03-07 |
Family
ID=36147033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040005089A KR100558505B1 (ko) | 2003-01-27 | 2004-01-27 | 안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060128763A1 (ko) |
EP (1) | EP1587792B1 (ko) |
JP (1) | JP2007528349A (ko) |
KR (1) | KR100558505B1 (ko) |
CN (1) | CN1777586A (ko) |
BR (1) | BRPI0407038A (ko) |
ES (1) | ES2500292T3 (ko) |
MX (1) | MXPA05007876A (ko) |
WO (1) | WO2004067512A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100821688B1 (ko) | 2006-08-10 | 2008-04-11 | (주)유케이케미팜 | 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법 |
KR100913791B1 (ko) * | 2006-07-21 | 2009-08-26 | 한미약품 주식회사 | (s)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100742432B1 (ko) * | 2005-12-27 | 2007-07-24 | 한미약품 주식회사 | 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법 |
KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
CA2749903C (en) | 2009-01-23 | 2016-09-06 | Jae Hyun Park | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
US9951009B2 (en) * | 2013-08-29 | 2018-04-24 | Cadila Healthcare Limited | Polymorphic form of pyrrole derivative and intermediate thereof |
JP6339364B2 (ja) * | 2013-12-27 | 2018-06-06 | カズマパートナーズ株式会社 | 無定形ブリモニジン酒石酸塩及びその製造方法 |
CN116332832A (zh) * | 2023-03-29 | 2023-06-27 | 安徽美致诚药业有限公司 | 一种马来酸左旋氨氯地平无定型晶型及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
KR950007228B1 (ko) | 1987-08-05 | 1995-07-07 | 화이자 인코포레이티드 | 암로디핀의 베실레이트염 |
KR100363566B1 (ko) * | 1998-11-20 | 2003-08-19 | 국제약품공업주식회사 | 무정형 세푸록심 악세틸의 제조방법 |
AU2001294354A1 (en) * | 2000-12-29 | 2002-07-16 | Bioorganics B.V. | Process for making amlodipine, derivatives thereof, and precursors therefor |
EP1309556B1 (en) * | 2000-12-29 | 2004-11-24 | Pfizer Limited | Amlodipine fumarate |
ATE315026T1 (de) * | 2000-12-29 | 2006-02-15 | Pfizer Ltd | Amlodipin-hemimaleat |
DE10112764A1 (de) * | 2001-03-16 | 2002-09-19 | Mann & Hummel Filter | Radialverdichter |
KR100452491B1 (ko) * | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
US6828339B2 (en) * | 2001-11-21 | 2004-12-07 | Synthon Bv | Amlodipine salt forms and processes for preparing them |
-
2004
- 2004-01-27 KR KR1020040005089A patent/KR100558505B1/ko active IP Right Grant
- 2004-01-27 CN CNA200480002970XA patent/CN1777586A/zh active Pending
- 2004-01-27 WO PCT/KR2004/000136 patent/WO2004067512A1/en active Search and Examination
- 2004-01-27 MX MXPA05007876A patent/MXPA05007876A/es active IP Right Grant
- 2004-01-27 JP JP2006502689A patent/JP2007528349A/ja active Pending
- 2004-01-27 EP EP04705547.0A patent/EP1587792B1/en not_active Expired - Fee Related
- 2004-01-27 ES ES04705547.0T patent/ES2500292T3/es not_active Expired - Lifetime
- 2004-01-27 BR BR0407038-0A patent/BRPI0407038A/pt not_active Application Discontinuation
- 2004-01-27 US US10/543,358 patent/US20060128763A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100913791B1 (ko) * | 2006-07-21 | 2009-08-26 | 한미약품 주식회사 | (s)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물 |
KR100821688B1 (ko) | 2006-08-10 | 2008-04-11 | (주)유케이케미팜 | 암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
EP1587792A1 (en) | 2005-10-26 |
KR100558505B1 (ko) | 2006-03-07 |
CN1777586A (zh) | 2006-05-24 |
ES2500292T3 (es) | 2014-09-30 |
JP2007528349A (ja) | 2007-10-11 |
EP1587792B1 (en) | 2014-08-27 |
US20060128763A1 (en) | 2006-06-15 |
WO2004067512A1 (en) | 2004-08-12 |
BRPI0407038A (pt) | 2006-01-17 |
EP1587792A4 (en) | 2011-03-09 |
MXPA05007876A (es) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0183027B1 (ko) | 류코트리엔의 작용에 대한 길항작용이 요구되는 질환의 치료용 약학 조성물 및 이의 제조 방법 | |
KR100452491B1 (ko) | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 | |
JPS62240660A (ja) | アムロジピンのベンゼンスルホン酸塩 | |
FI74705B (fi) | Foerfarande foer framstaellning av nya kristallina bensotiazindioxidsalter. | |
AU661483B2 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
JP2009542633A (ja) | ピロロピリミジノン誘導体の塩およびその製造方法 | |
KR100558505B1 (ko) | 안정한 무정형 암로디핀 캠실레이트, 이의 제조방법 및이를 포함하는 경구투여용 조성물 | |
JP2008514691A (ja) | 薬学的に純粋な非晶質塩酸ドネペジルを製造するための精製されたマレイン酸ドネペジルの使用 | |
SK4232001A3 (en) | New crystal modification iii of torasemide | |
US5149523A (en) | Polystyrenesulfonate-drug complex and solid dosage forms thereof | |
KR20080055356A (ko) | 보관안정성이 우수한 클로피도그렐 함유 포접 복합체 | |
JP2000281561A (ja) | 新規溶媒法固体分散体製剤 | |
EP2698371B1 (en) | Novel addition salt of an inhibitor of platelet aggregation | |
WO2004043972A1 (fr) | Nouvelle forme cristalline d'adefovir dipivoxil et sa composition | |
KR100841409B1 (ko) | 암로디핀 겐티세이트 염과 이의 제조방법 | |
JP2009544695A (ja) | (s)−(−)−カムシル酸アムロジピンまたはその水和物及びそれを含む薬学的組成物 | |
US20080014263A1 (en) | Amorphous eprosartan mesylate and process for the preparation thereof | |
WO2004083180A1 (en) | Novel crystalline forms of levetiracetam | |
CN113087656B (zh) | 一种无定型苯磺酸左旋氨氯地平 | |
WO2013093753A1 (en) | Ivabradine hydrochloride premix | |
RU2766288C2 (ru) | Аморфная форма 4-{ 4-[({ [4-хлор-3-(трифторметил)фенил]амино} карбонил)-амино]фенокси} -n-метилпиридин-2-карбоксамида тозилата (варианты), способ её получения и применение для лечения онкологических заболеваний | |
KR950007228B1 (ko) | 암로디핀의 베실레이트염 | |
KR100742134B1 (ko) | 결정성S-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-c]피리딘-5(4H)-일)아세테이트·캄실레이트를 포함하는약학적 조성물 | |
Wilkerson et al. | A bis-[N-3-(1-hydroxy-1-methyl-ethyl)-benzyl)-cyclic urea as a HIV protease inhibitor | |
KR100504985B1 (ko) | 암로디핀 니코티네이트 결정성 2수화물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20141215 Year of fee payment: 10 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140902 Effective date: 20150202 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140618 Effective date: 20150202 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140715 Effective date: 20150202 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140905 Effective date: 20150202 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20140901 Effective date: 20150306 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150313 Effective date: 20150528 |
|
FPAY | Annual fee payment |
Payment date: 20151215 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161216 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20181218 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20191226 Year of fee payment: 15 |